TP53 突变与基线淋巴细胞提示复发/难治性弥漫大 B 细胞淋巴瘤对 glofitamab 的应答

Although CAR-T cell therapy has emerged as a promising therapeutic option for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), long manufacturing time, high cost and toxicities limit its clinical use. T-cell engagers (TCEs) including glofitamab may address these unmet needs, but real-world data remain scarce. This real-world study (NCT06481826) enrolled 30 Chinese patients. The median prior treatment lines were 2 (2-5) and 90% had no prior CAR-T therapy. After a median follow-up of 15 months, the overall response rate (ORR) was 66.

7%. The 1-year progression-free survival (PFS) was 62. 5% with a median PFS of 15 months. The 1-year overall survival (OS) was 70%. Univariate analysis identified more than 1 extranodal involvement site, TP53 mutation and low baseline lymphocytes as poor prognostic factors. Safety profile was manageable. 43. 3% patients developed cytokine release syndrome (CRS, mostly grade 1-3) and 3. 3% had grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS). The hematologic toxicity was mostly mild. COVID-19 infection occurred in 20% of patients.

This study demonstrates that glofitamab is effective and well-tolerated in Chinese R/R DLBCL patients. Earlier lines of glofitamab may be more beneficial, while expanded cohorts are warranted to explore its efficacy among patients with multiple extranodal lesions, TP53 mutations and low baseline lymphocytes.